Replies to post #796702 on NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

Senti, I don't see a multiple applied to your pricing of NWBO! Thanks for doing the math for us. Now we can project the price at a fair multiple. I think it's very hard (impossible?) to rule out a multiple even on the first day after MHRA decision. I believe there are many investors waiting on approval to get in and they know NWBO's forward capabilities to dominate the cancer market.

If you're using a current market cap valuation the multiple is already baked in. You don't add more multiples.

You apply a multiple when projecting valuation using revenues, which is not the operation that Senti just performed.

Wow it is scary that I'm invested in the same thing as some of yall.

[WideEyed]

Beartrap,

I agree with you. The markets are forward looking. There are many people with a lot invested here. Initially, many people will want to sell a little; after that the institutions/funds will take over buying. Sawston capacity is just over $2 billion in revenue per year. Six months out full capacity revenue for Sawston would be $1 billion; think the analysts will give us $500 million out of the gate. Using a 20x multiplier because we’re an exciting new biotech, NWBO stock price = ($500 X 20x) / 1.5 billion shares = $6.66 per share soon after approval. Add in $ from Franchises/Partnerships and we’re over $10 soon after approval.